Eczema drug Dupilumab's skin gene secrets revealed in small study

NCT ID NCT03293030

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the eczema drug dupilumab (Dupixent) affects immune cells and genes in the skin. Seventeen adults with moderate-to-severe eczema took the drug, and researchers measured changes in skin samples over 12 weeks. The goal was to understand the biological effects of dupilumab on eczema lesions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dupilumab (Dupixent)

What this could lead to

If successful, this could help explain how dupilumab works in the skin to improve eczema treatment.

What could go wrong

This was a very small study with only 17 people and no comparison group, so results may not apply to everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCSF Psoriasis and Skin Treatment Center

    San Francisco, California, 94118, United States